Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR)

Tipranks - Thu Apr 16, 8:22AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR).

Claim 30% Off TipRanks

Eli Lilly & Co (LLY)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1300.00. The company’s shares closed last Tuesday at $922.50.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 8.6% and a 52.2% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Taysha Gene Therapies. ;'>

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1247.71, representing a 34.9% upside. In a report issued on March 30, TipRanks – xAI also upgraded the stock to Buy with a $975.00 price target.

See the top stocks recommended by analysts >>

Immunocore Holdings (IMCR)

Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Immunocore Holdings today and set a price target of $38.00. The company’s shares closed last Tuesday at $31.69, close to its 52-week low of $27.19.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 20.6% and a 48.1% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

Immunocore Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $62.67.

Read More on LLY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.